Dear Editor,

We read with interest the interpretations of O.Y. et al. related to our article on our pediatric case of anaphylaxis that developed in relation with midazolam in Pediatric Hematology and Oncology Ward,. However, we observed that the context and objective of our article were not understood. In our article, we aimed to address the risk of anaphylaxis with midazolam, which is commonly used outside the operation room, and therefore, we did not state the routine sedation-analgesia schema being applied in our hospital ([@ref1]). Although sedation-analgesia used in the childhood age group is outside the context of our article, ketamine could not be administered in our patient because his general status deteriorated following administration of midazolam. Use of midazolam and ketamine in painful procedural sedation-analgesia in children is already recommended and well known ([@ref2]).

We administered intravenous adrenaline because our patient developed bradycardia, his consciousness deteriorated, and a severe picture of anaphylaxis developed. Although intravenous adrenaline can be administered in cases of severe anaphylaxis, we are also in favor of primarily preferring intramuscular adrenaline in anaphylaxis because of its cardiac adverse effects ([@ref3], [@ref4]). The finding that anaphylaxis did not develop with previous administrations of midazolam in our patient may be explained by the possibility that previous exposures caused sensitivity and anaphylaxis developed with subsequent administration ([@ref5]).
